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Abstract
Background: Various strategies have been developed to transfer tumor-specific antigens into antigen presenting
cells in order to induce cytotoxic T cell responses against tumor cells. One approach uses cellular vaccines based
on fusions of autologous antigen presenting cells and allogeneic tumor cells. The fusion cells combine antigenicity
of the tumor cell with optimal immunostimulatory capacity of the antigen presenting cells.
Microsatellite instability caused by mutational inactivation of DNA mismatch repair genes results in translational
frameshifts when affecting coding regions. It has been shown by us and others that these mutant proteins lead to
the presentation of immunogenic frameshift peptides that are - in principle - recognized by a multiplicity of
effector T cells.
Methods: We chose microsatellite instability-induced frameshift antigens as ideal to test for induction of tumor
specific T cell responses by semiallogenic fusions of microsatellite instable carcinoma cells with CD40-activated B
cells. Two fusion clones of HCT116 with activated B cells were selected for stimulation of T cells autologous to the
B cell fusion partner. Outgrowing T cells were phenotyped and tested in functional assays.
Results: The fusion clones expressed frameshift antigens as well as high amounts of MHC and costimulatory
molecules. Autologous T cells stimulated with these fusions were predominantly CD4
+, activated, and reacted
specifically against the fusion clones and also against the tumor cell fusion partner. Interestingly, a response toward
6 frameshift-derived peptides (of 14 tested) could be observed.
Conclusion: Cellular fusions of MSI
+ carcinoma cells and activated B cells combine the antigen-presenting capacity
of the B cell with the antigenic repertoire of the carcinoma cell. They present frameshift-derived peptides and can
induce specific and fully functional T cells recognizing not only fusion cells but also the carcinoma cells. These
hybrid cells may have great potential for cellular immunotherapy and this approach should be further analyzed in
preclinical as well as clinical trials. Moreover, this is the first report on the induction of frameshift-specific T cell
responses without the use of synthetic peptides.
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Background
The last decades have witnessed the identification of an
increasing number of truly specific tumor antigens. Not
all antigens carried by human neoplasias have similar
immunogenic properties. Somatic mutations should
have the highest immunological impact. Such mutations
create neoantigenic epitopes which are completely for-
eign to the immune system and can serve as antigenic
determinants. The presence of high-grade microsatellite
instability (MSI
+), for instance, is evidence of ongoing
mutagenesis in a fraction of colorectal cancer (CRC).
MSI occurs subsequent to DNA mismatch repair inacti-
vation and causes insertion or deletion mutations at
short repetitive DNA sequences located throughout the
genome. MSI
+ tumors are typically infiltrated by predo-
minantly activated cytotoxic T lymphocytes and display
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any medium, provided the original work is properly cited.increased neoplastic cell apoptosis. These features argue
for a strong antitumoral immune response directed
against potent tumor rejection antigens [1-3]. We and
others demonstrated that frameshift-neopeptides (FSP)
encoded by mutations of microsatellites located in cod-
ing sequences are highly immunogenic [4-10]. These
studies documented that FSPs represent true MSI
+
tumor-specific antigens.
Clinical cancer vaccination studies are essentially
b a s e do nt h ek n o w l e d g eo fa tl e a s to n et u m o rs p e c i f i c
antigen. However, reported response rates from those
trials are unsatisfying. Among the reasons made respon-
sible for failures are immune evasion of tumor cells, dis-
ease-specific immune suppression and poor intrinsic
immunogenicity of many tumors.
Cellular fusions of antigen-presenting cells (APC) with
tumor cells are a relatively simple and effective way to
obtain highly immunogenic vaccines which combine the
antigen-presenting properties of professional APC with
a full repertoire of tumor antigens [11-14]. Proof-of-
principle clinical studies have also been performed
[15-17].
Most researchers have focused on dendritic cells as
APCs. However, antigen-unspecific B cells can be used
as an alternative source of efficient APCs when properly
activated by engagement of CD40 [18,19]. Arguments in
favour of these CD40-activated B cells (CD40 Bs) are
ease of isolation, activation and expansion [20].
Very recently, we optimized the generation of cellular
fusions consisting of CD40 Bs and MSI
+ CRC cells [21].
In the present study, we have evaluated the potency of
T cell induction by semiallogenic cell fusions of a MSI
+
tumor cell line and CD40 Bs. In particular, we have
examined the potency of in vitro induction of T cells
specifically recognizing MSI-induced FSPs derived from
the tumor cell line fusion partner. The data presented
here show that MSI
+/CD40 B cell hybrid cells induce
potent anti-MSI T cell responses, indicating a great
potential as immunogens in cancer immunotherapy and
providing a rationale for future use in clinical trials.
Methods
Cell lines and peptides
All tumor cell lines were obtained from ATCC and from
cell line services (Eppelheim, Germany) and grown in
RPMI 1640 medium supplemented with 10% fetal calf
serum, 2 mmol/L L-glutamine and antibiotics. Tissue
culture media and supplements were purchased from
PAA (Cölbe, Germany) unless indicated otherwise.
Peptides were obtained from the Peptide Synthesis
Facility at the DKFZ. They were dissolved in DMSO
and further diluted in PBS. Peptides spanned the entire
frameshift-sequence of Caspase-5 (-1) (40 mer; contain-
ing 25 aa neo- and 15 aa wt-sequence), OGT (-1) (34
mer; 19 aa neo-, 15 aa wt), Sec63 (-1) (42 mer; 27 aa
neo-. 15 aa wt), TGFbRII (-1) (49 mer; 34 aa neo-, 15 aa
wt), Taf1B (-1) (40 mer; 25 aa neo-, 15 aa wt), HT001
(-1) ( 47 mer; 32 aa neo-, 15 aa wt), MSH-3 (-1) (40
mer; 31 aa neo-, 9 aa wt) and AIM2 (-1) (20 mer; 13 aa
neo-, 7 aa wt). Overlapping 20 mer peptides were
synthesized for U79260 (-1) (49 aa neo-, 1 aa wt); AC-1
(-1) (58 aa neo-, 2 aa wt); FLJ11053 (-1) (32 aa neo-, 9
aa wt) together with FLJ378 (-2) (37 aa neo-, 9 aa wt);
DAMS (-1) (14 aa neo-, 9 aa wt) together with DAMS
(-2) (30 aa neo-, 9 aa wt) and UST3 (-1) (66 aa neo-, 4
aa wt) respectively (for peptide sequences see [9]).
B cell and T cell purification
Peripheral blood mononuclear cells were isolated from
heparinized blood of a healthy HLA-A02
+ donor using
Ficoll-density gradient centrifugation. Whole CD3
+ T
cells were obtained from PBMCs by magnetic depletion
of non-T cells using the MACS Pan T Cell Isolation Kit
II (Miltenyi; Bergisch Gladbach, Germany) according to
manufacturer’s instructions. The remaining non-T cells
were subsequently used as a source for B cells. All pro-
cedures using human cells were approved by the Ethics
Committee of the University of Heidelberg in accor-
dance with the provisions of the declaration of Helsinki
(as revised in Edinburgh 2000). An informed consent in
written was obtained prior to the blood sampling
procedure.
Culture of CD40 Bs
The culture of CD40 Bs was performed as described
[22]. Briefly, B cells were stimulated via NIH3T3 stimu-
lator cells stably expressing human CD154. Lethally irra-
diated stimulator cells (60 Gy) were plated on 6-well
plates (0.35 × 10
5 cells/well) and cultured overnight.
After removing medium, magnetic depleted non Tc (2 ×
10
6 cells/ml) were resuspended in Iscove’sm o d i f i e d
DMEM (IMDM) supplemented with 10% human AB
serum, 5 μg/ml insulin, 50 μg/ml transferrin and 15 μg/
ml gentamicin in the presence of IL-4 (10 IU/ml) and
cyclosporin A (5.5 × 10
-7M). Every 3-5 days cells were
transferred to new plates containing fresh irradiated sti-
mulator cells. All cytokines were obtained from Promo-
Cell, Heidelberg, Germany.
Fusion of MSI
+ tumor cells with CD40 Bs
HCT116 tumor cells and CD40 Bs from a healthy HLA-
A02
+ donor were washed in serum-free RPMI 1640
medium, pelleted and stained with 5 μM5 - c h l o r o -
methylfluorescein diacetate or 5 μM 5-(and 6)-(((4-
chloromethyl) benzoyl)-amino) tetramethyl-rhodamin in
PBS, respectively. Cells were incubated for 45 min at 37°
C, washed and resuspended in serum-free RPMI 1640
medium. After a second incubation period, stained cells
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were mixed with tumor cells at a CD40 Bs:tumor cell
r a t i oo f2 : 1a n de x p o s e d5m i nt o4×1 0
-5MS D S .C e l l
suspension was pelleted and 1 ml 50% polyethylene gly-
col 1500 (Roche, Mannheim, Germany) was added over
5 min to the CD40 Bs/tumor cell pellet while stirring
the cells continuously. The polyethylene glycol solution
was then diluted by slow addition of first 1 ml warmed
serum- and phenol red-free medium over 3 min with
continued stirring and then another 10 ml of this med-
ium over 5 min. After centrifugation cells were resus-
pended in phenol red-free RPMI 1640 supplemented
with 10% FCS. Cells were cultured 24 h before the
fusion efficacy was analyzed by flow cytometry. Fused
cells consisting of MSI
+ colon carcinoma cells HCT116
and CD40 Bs, which exhibited dual fluorescence, were
cloned by limiting dilution. Briefly, fused cells were
seeded under limiting dilution conditions (0.7 cells/well)
in 96-well plates containing a final volume of 200 μl
RPMI 1640 with 10% FCS. Outgrowing fusion clones
were comprehensively screened concerning the cell sur-
face expression of HLA-A02, MHC class I and II mole-
cules and costimulators (CD40, CD80, and CD86). For
all subsequent experiments, two clones were selected
and designated as Fc1 and Fc2.
T cell stimulation with semiallogenic cellular fusion clones
Fusion clones were collected from cell culture, irradiated
(200 Gy) and added to purified CD3
+ autologous T cells
at a ratio of 3:1 (Tc:fusion cell) in IMDM supplemented
with 10% human AB serum, 5 μg/ml insulin, 50 μg/ml
transferrin and 15 μg/ml gentamicin in the presence of
IL-7 (10 IU/ml ). Cells were plated at a density of 2 ×
10
6 T cells in 1 ml of medium per well of a 24 well
plate. For T cell restimulation this was repeated weekly.
IL-2 was first given at day 21 (10 IU/ml), also at day 24
and from day 28 on only IL-2 was used instead of IL-7.
CD4
+ T cells and CD8
+ T cells were obtained from
the whole T cell population by magnetic cell sorting
using MACS CD4 and CD8 microbeads (Miltenyi; Ber-
gisch Gladbach, Germany) according to manufacturer’s
instructions. CD4 microbeads were used for the sorting
of CD8
+ T cells and CD8 microbeads for the sorting of
CD4
+ T cells. Selection of T cells was checked by flow
cytometry. CD4
+ T cells and CD8
+ T cells were restimu-
lated separately with irradiated fusion clones and IL-2 as
described for the whole T cell population.
IFN-g ELISpot assay
ELISpot assays were performed using nitrocellulose-96-
well plates (Multiscreen; Millipore, Bedford, USA) cov-
ered with mouse anti-human IFN-g mAb (Mabtech, Swe-
den) and blocked with serum containing medium.
Initially, in vitro primed T cells (1 × 10
4) were stimulated
in triplicates with 2 × 10
4 CD40 Bs, HCT116, Fc1 or Fc2
cells per well as targets. Afterwards T effector cells (1 ×
10
4) were plated in sixplicates with 2 × 10
4 peptide-
loaded autologous CD40 Bs. Peptides were added at a
final concentration of 10 μg/ml. After incubation for 16 h
at 37°C, plates were washed, incubated with biotinylated
rabbit anti-human IFN-g for 4 h, washed again, incubated
with streptavidin-alkaline phosphatase for 2 h, followed
by a final wash. Spots were detected by incubation with
NBT/BCIP (Sigma-Aldrich, Steinheim, Germany) up to 1
h. Reaction was stopped with water and after drying
spots were counted. The deduced frequency of peptide-
specific T cells was calculated by subtracting mean num-
bers of spots in the no-peptide control from mean num-
bers of spots in the peptide-stimulated sample. Negative
values were scored as zero.
After proving the assumption of normality, differences
between negative control and FSP-containing wells were
determined by using the unpaired Student’st - t e s t .I f
normality failed, the nonparametric Mann-Whitney U-
Test was applied. The tests were performed by using
Sigma-Stat 3.0 (Jandel Corp, San Rafael, CA). The criter-
ion for significance was set to p < 0.05.
Determination of cMS mutation pattern
G e n o m i cD N Aw a si s o l a t e df r o mm i c r o d i s s e c t e dt u m o r
sections using the DNeasy Tissue Kit (Qiagen, Hilden,
Germany). For analysis of cMS, the corresponding geno-
mic regions were amplified as described previously [23].
PCR products were analyzed using an ABI3100 genetic
analyzer and Genescan Analysis Software (Applied Bio-
systems, Darmstadt, Germany). Instability was scored, if
comparison with amplification products of normal tissue
revealed the occurrence of novel peaks or if the ratio of
corresponding peak areas was ≤0.5 or ≥2.
Cytotoxicity assays
Standard chromium release assays were performed as
described [24]. Tumor target cells were labelled with
100 μCi [
51Cr]-sodium chromate for one hour at 37°C.
For each experimental condition, cells were plated in V-
bottomed 96-well plates with 10
3 target cells/well in tri-
plicate. Varying numbers of CTL were added to a final
volume of 200 μl and incubated for 4 h at 37°C. Sponta-
neous and maximal release was determined in the pre-
sence of medium alone or of 1% NP-40. Supernatants
(100 μl/well) were harvested and counted in a gamma-
counter. The percentage of specific lysis was calculated
as follows: 100% × [experimental release - spontaneous
release]/[maximal release - spontaneous release].
FACS analysis
Expression of the following surface markers was ana-
lyzed: MHCI (W6/32), HLA-A2 (BB7.2), MHCII (12G6),
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Page 3 of 10CD3 (OKT3), CD28 (CD28.2) with unlabeled primary
antibodies and FITC-labelled goat anti-mouse IgG’s
(Dianova, Hamburg, Germany) as second antibody. Cells
treated without primary antibody were used as negative
control. CD4 (RPA-T4), CD8 (RPA-T8), CD19 (HIB19),
CD45RO (UCHL1), CD50 (101-1D2, Cymbus Biotech-
nology, UK), CD58 (1C3 AICD58.6), CD80 (BB1/B7-1),
CD86 (B70/B7-2) and CD102 (B-T1; Serotec, Oxford,
UK) were directly FITC-conjugated, whereas CD25 (M-
A251), CD69 (FN50) and CD71 (SOM4D10, Diatec,
Oslo, Sweden) were PE-conjugated. Isotype-matched
monoclonal antibodies were used as a negative control.
For intracellular staining, T cells were incubated with
the protein transport inhibitor brefeldin A (2 μg/ml,
Serva, Deisenhofen, Germany) for 15 h at 37°C. After
two washes with PBS/1% FCS, cells were fixed with cold
4% paraformaldehyde (PFA, Serva) in PBS for 10 min at
4°C, washed twice with PBS/1% FCS and permeabilized
with saponine buffer (PBS, 0,1% saponine, 1% FCS and
0,01 M Hepes) for 10 min at room temperature. T cells
were subsequently stained for intracellular cytokines
with PE-labelled anti-IFN-g (4SB3), anti-TNF-a(Mab11),
anti-IL-2 (MQ1-17H12) mAbs, or IgG1 isotype control
mAb in saponine buffer for 20 min at 4°C. Cells were
washed twice with saponine buffer and resuspended in
PBS/1% FCS before measurement. Intracellular perforin
was detected with PE-labelled anti-perforin (dG9) mAb.
For analysis of intracellular granzyme B, cells were incu-
bated with anti-granzyme B (2C5/F5, Serotec) mAb fol-
lowed by FITC-labelled goat anti-mouse IgG’s. Cells
treated without primary antibody were used as negative
control. Cell surface and intracellular immunofluores-
cences were obtained using FACSCalibur (BD Bios-
ciences, Heidelberg, Germany) and CellQuest software.
Typically, 20.000 cells were acquired from each sample.
Cells to be analyzed were first gated according to rea-
s o n a b l es i z ea n dg r a n u l a r i t yi nt h ef o r w a r d / s i d e w a r d
scatter plot. Gated cells were than blotted into histo-
gram blots. Mean intensitieso ft h en e g a t i v ec o n t r o l
were between 2 and 10. For determination of percen-
tages of positive cells, the cut-off included a maximum
of 2% of the events in the negative control. Antibodies
and signal detection reagents were obtained from BD
Biosciences unless stated otherwise.
Results
Semiallogenic cellular fusion and selection of fusion cell
clones
The CD40 Bs used to generate fusions were derived from
a healthy volunteer with neither a family history of her-
editary non-polyposis colorectal cancer nor any other
known severe disease, in particular no tumor. Therefore,
the T cells of this donor can be considered as naive with
regard to prior contact with MSI-induced frameshift
mutations. As tumor cell fusion partner, the MSI
+ CRC
cell line HCT116 was chosen because the mutational sta-
tus of many coding microsatellites (cMS) is well known
(Table 1), it shares human leukocyte antigen (HLA)-A02
as restriction element with the CD40 Bs of the healthy
donor and it has been shown to be accessible to lysis by
cytotoxic T lymphocytes (CTL) [8,10]. Semiallogenic cel-
lular fusions were performed in the presence of polyethy-
lene glycol. The fusion efficiencies were between 10 and
15% [data not shown] and thus very similar to published
data [21]. However, additionally to fresh fusions we
decided to obtain fusion cell clones as this allowed us to
select variants expressing mutations in cMS giving rise to
FSPs with high immunogenic potential and additionally
high amounts of major histocompatibility complex
(MHC) and of the costimulatory molecules CD40, CD80
and CD86. Extensive characterization of established
fusion clones was performed and two fusion cell clones
(Fc1 and Fc2) expressing many FSPs (Table 1) and higher
amounts of MHC and costimulatory molecules as
HCT116 (Table 2) were selected as stimulator cells in
subsequent T cell stimulations. Data of two fusion clones
expressing low amounts of MHC and costimulatory
molecules are additionally shown (Table 2).
In vitro T cell stimulations
Isolated peripheral T cells autologous to the CD40 Bs
used as fusion partner were weekly stimulated with
Table 1 Analysis of Microsatellite instability (MSI)
Microsatellite markers HCT116 Fc1 Fc2
BAT25
1 ++ +
BAT26
1 ++ +
MFD15
1 ++ +
D5S346
1 +- -
D2S123
1 ++ -
CASP5 wt/-1 wt/-1 wt
OGT wt wt wt
SEC63 wt wt/-1 wt/-1
TGFB2R wt wt wt
Taf1B -3/-2/wt -2/wt -2/wt
HT001 -1/-2 -1 -1
MSH3 -1 -1 -2
U79260 -4 -4 -5
AC-1 (c4orf6) wt wt wt
AIM2 -1 -1 wt/-1
FLJ20378 -3 -3 -3
FLJ11053 wt/-1 wt/-1 wt
DAMS n.d. n.d. n.d.
UST3 -2 wt/-1 wt/-2
1 MSI is indicated by a “+”.
2 length of cMS alleles analyzed are indicated.
Wt (wildtype) and observed length variations are displayed.
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protocol of in vitro T cell stimulation [10]. As controls,
T cells were also stimulated with autologous CD40 Bs
and with HCT116 cells. In the first five weeks, all bulk
T cell cultures grew moderately but in the following two
weeks the T cells stimulated with HCT116 and CD40 Bs
decreased followed by the fresh fusions stimulated T
cells (Figure 1A). Sustained growth with fold increases
exceeding 10 was reached solely by the T cell cultures
stimulated with the fusion cell clones Fc1 and Fc2 (Fig-
ure 1A). Consequently, all subsequent detailed analyses
were restricted to the latter two cultures. Phenotypical
analysis proved that the cultures consisted of pure T
cells with a slightly dominance of CD4
+ cells but a
clearly activated status judged from the high expression
levels of CD25, CD45RO, CD69 and CD71 (Table 3).
The Fc1-stimulated T cells produced higher levels of
interferon (IFN)-g and Perforin. Granzyme B was detect-
able in high levels in both T cell populations (Table 3).
Table 2 Expression of cell surface molecules on CD40 Bs,
HCT116 and fusion clones 1 to 4
mean fluorescence intensity
antigen CD40 Bs HCT116 Fc1 Fc2 Fc3 Fc4
HLA-A0201 1 285.5 74.4 163.9 177.5 575.5 176.7
MHC class I 1 768.0 496.9 1 006.0 909.5 1736.8 800.8
MHC class II 524.8 7.4 39.1 40.5 11.9 9.0
CD80 179.8 6.3 9.7 16.5 4.8 8.5
CD86 117.4 5.4 11.7 13.5 5.7 7.7
CD40 393.9 21.0 50.2 50.5 44.2 27.8
Fc1 and Fc2 have been used in subsequent experiments
Fc3 and Fc4 have not been analysed further because of low expression of
MHC class II.
1
10
100
1000
0 7 14 21 28 35 42 49 56 63 70
days in culture
g
r
o
w
t
h
 
f
a
c
t
o
r
HCT116
Fc1
Fc2
fusion d1
CD40Bs
A B
TcFc1
0 50 100 150 200 250 300 350
CD40Bs
HCT116
Fc1
IFN-γ releasing cells / 104
Figure 1 Characteristics of T cells stimulated with fusion and control cells. A. Growth curve of T cells stimulated with fresh fusions (d1),
Fc1, Fc2, autologous CD40 Bs and HCT116 cells. Fusion clones (Fc1 and Fc2) generated from autologous CD40 Bs and HCT116 were able to
stimulate long-lasting growth of autologous T cells compared to CD40 Bs or HCT116 alone. Days in culture are given together with the
calculated growth factor accumulated over the culture time. B. ELISpot analysis of T cells stimulated with Fc1. T cells (1 × 10
4 cells/well) were
stimulated with 2 × 10
4 CD40 Bs, HCT116 and Fc1 cells per well as targets. Analysis was performed in triplicates. The number of IFN-g releasing
activated T cells for the total number of cells analyzed (10
4) is given together with the standard deviation.
Table 3 FACS analysis of Tc generated against Fc1 and
Fc2
% positive cells
antigen TcFc1 TcFc2
CD3
1 97.0 97.5
CD4
1 53.9 57.4
CD8
1 46.0 43.2
CD28
1 37.2 43.6
CD45RO
1 79.7 81.7
CD25
1 27.5 28.2
CD69
1 29.3 36.1
CD71
1 89.2 89.2
IFN-g
2 26.9 15.3
Perforin
2 25.8 3.9
Granzyme B
2 63.7 74.4
1 d37 of Tc culture
2 d72 of Tc culture
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Next, we addressed whether the T cells recognized the
fusion clones used for stimulation. A representative ELI-
Spot-analysis of Fc1-stimulated T cells is presented in
Figure 1B. As expected, the T cells readily secreted IFN-
g in response to Fc1 (3.2%). The autologous B cells were
not recognized (< 0.1%) but HCT116 could provoke a
minor reaction (0.4%). This weak reaction towards the
tumor cell fusion partner HCT116 did however not pre-
vent killing of HCT116 by Fc1 and Fc2-stimulated T
cells as subsequently tested in cytotoxicity experiments
(Figure 2A). Of note, this killing could be enhanced by
pre-treatment of HCT116 with IFN-g leading to an
upregulation of MHC molecules and immune
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Figure 2 Cytotoxic reactivity ofF c - s t i m u l a t e dTc e l l s . T cells were generated against Fc1 (TcFc1,l e f t )a n da g a i n s tF c 2( T c F c 2 ,r i g h t ) .A.
Specific cytotoxic activity against the MSI
+, HLA-A02
+ colon carcinoma cell line HCT116 is shown with and without prior IFN-g-treatment (200 U/
ml). Both TcFc1 and TcFc2 cultures lack reactivity towards autologous CD40 Bs. B. Specific lysis of MSI
+, HLA-A02
+ colon carcinoma cell line
Colo60H is shown in contrast to that of microsatellite stable, HLA-A02
+ colon carcinoma cell lines SW707 and SW480. Lack of reactivity against
NK sensitive K562 excludes NK cell activity. C. Cytotoxic potential of TcFc1 and TcFc2 towards the MSI
+, HLA-A02
+ prostate carcinoma cell line
LNCaP compared to the MSI
+ HLA-A02
- prostate carcinoma cell line DU-145. Target cells were labelled with [
51Cr]-sodium chromate for 1 h.
Different effector to target cell ratios (E:T ratio) are shown. All results are displayed as the mean and standard deviation from three replicate
wells.
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to contaminating NK cells in the T cell bulk cultures,
since the classical NK cell target cell line K562 was not
recognized (Figure 2B). Testing of another three HLA-
A2
+ colorectal cell lines revealed no recognition of the
MSI
- cell lines SW480 and SW707 but recognition of
the MSI
+ cell line Colo60H (Figure 2B). Finally, Fc1 and
Fc2-stimulated T cells’ reactivity was tested against the
MSI
+ prostate carcinoma cell lines LNCaP (HLA-A2
+)
and DU-145 (HLA-A2
-) (Figure 2C). Both T cell lines
strongly reacted against the MSI
+ and HLA-A2
+ cell
line LNCaP whereas they did not kill the MSI
+ but
HLA-A2
- DU-145 (Figure 2C).
Fc1CD4
+ T cells have higher proliferative and Fc1CD8
+ T
cells higher cytotoxic potential
In order to elucidate the contribution of CD4
+ and CD8
+
T cells towards tumor cell recognition, we negatively sepa-
rated the Fc1-stimulated T cells magnetically to high pur-
ity. As can be depicted from Figure 3A, the CD4
+ T cells
Fc1 had greater proliferative potential. However, the CD8
+
T cells Fc1 better recognized HCT116 as well as LNCaP
cells both in IFN-g ELISpot as well as in cytotoxicity
experiments (Figures 3B and 3C). As an additional obser-
vation, the better recognition of Fc1 compared to HCT116
could be attributed to the CD8
+ T cells Fc1 (Figure 3B).
These functional data match with the results of
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Figure 3 Analysis of selected CD4
+ and CD8
+ Fc-stimulated T cells. A. Growth of CD4
+ and CD8
+ T cells stimulated with Fc1 after magnetic
separation. Total days in culture are given together with the calculated growth factor accumulated over the culture time starting after magnetic
separation. B. ELISpot analysis of CD4
+ and CD8
+ T cells generated against CD40 Bs/HCT116 fusion clone 1 (Fc1). T cells (1 × 10
4 cells/well) were
stimulated with 2 × 10
4 CD40 Bs, HCT116 or Fc1 as targets. The number of specific IFN-g releasing activated T cells (spots) among the total
number of T cells analyzed (10
4) and the standard deviation from three replicate wells are given. C. Cytotoxic activity of CD4
+ and CD8
+ T cells
(CD4
+ Tc, CD8
+ Tc) generated against CD40 Bs/HCT116 fusion clone 1. Left: Specific reactivity of CD4
+ Tc and CD8
+ Tc against MSI
+ HLA-A02
+
colon carcinoma cell line HCT116. Right: Specific lytic potential of CD4
+ Tc and CD8
+ Tc against the MSI
+ HLA-A02
+ prostate carcinoma cell line
LNCaP. Targets were labelled with [
51Cr]-sodium chromate for 1 h. Different effector to target cell ratios (E:T ratio) are shown. All results are
displayed as the mean and standard deviation from three replicate wells.
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Page 7 of 10phenotypic FACS analysis. CD8
+ TcFc1 showed stronger
expression of IFN-g, interleukin (IL)-2 and perforin (Figure
4A), whereas CD4
+ TcFc1 produced more tumor necrosis
factor (TNF)-a and granzyme B (Figure 4B).
Fc1 and Fc2 T cell cultures contain FSP-specific T cells
S i n c ew eh y p o t h e s i z e dt h a ta tl e a s tap r o p o r t i o no ft h e
fusion clone stimulated T cells are specific for MSI-
induced FSPs, we tested the Fc1-stimulated T cells for
recognition of FSPs in IFN-g ELISpot-assays. Here, we
observed a response towards four of the 14 FSPs
included into this analysis (Figure 5). This proves that
fusions of MSI
+ cells with APC can functionally present
FSPs to T cells which in turn can be activated and gain
the potential to attack MSI
+ tumor cells.
Discussion
Data presented here confirm our previous findings that
cell hybrids of human MSI
+ tumor cells and CD40 Bs as
APC can easily be generated [21]. Fusion cells retain
desired characteristics of both fusion partners; in parti-
cular the expression of MSI-induced FSPs and of func-
tional antigen processing and presentation machinery
together with potent immunostimulatory capacity. In
t h ep r e s e n ts t u d yw ew o r k e dw i t hs t a b l ef u s i o nc e l l
clones instead of highly purified fresh fusion cells we
described recently [21]. This approach was chosen to
ensure a uniform fusion cell population concerning the
immunostimulatory phenotype and the expression of
FSPs. Indeed, the distribution of these features was het-
erogeneous between different clones. Others have
shown that careful selection of fusion clones may be
essential for successful T cell stimulation [25].
Good arguments in favour of CD40 Bs as APC are the
possibilities to easily isolate them even out of minimal
amounts of peripheral blood, to propagate them for
longer time periods and lastly the outstanding T cell sti-
mulatory capacity of fully activated B cells [8,21,22].
The disclosure of the molecular pathways leading to
MSI has led us and others to hypothesize and prove
173.9
99.1%
29.6
36.7%
131.4
35.4%
CD8+ TcFc1
31.9 
83.3%
148.7 
93.3%
211.5 
29.5%
8.1 
5.0%
191.1 
81.4%
548.0 
99.3%
342.3
97.0%
41.4
65.6%
84.7
13.5%
CD4+ TcFc1
A
B
Figure 4 FACS analysis of CD4
+ and CD8
+ Fc-stimulated T cells. After magnetic separation of CD4 and CD8 T cells followed by two
additional rounds of stimulation with Fc1, the T cells were analyzed for expression of CD4/CD8 and of the indicated intracellular cytokines. A.
Fc1 CD8
+ T cells B. Fc1 CD4
+ T cells. The percentages of positive cells are indicated together with the mean fluorescence intensities. Isotype
matched negative controls are indicated by dotted lines.
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Page 8 of 10that when affecting coding regions, this will ultimately
give rise to FSPs with high immunogenic potential
[4-10]. Beyond the documentation that FSPs represent
true MSI
+ tumor-specific antigens, these studies suggest
a tumor-immunological model character of MSI
+
tumors. Large numbers of specific FSPs have been iden-
tified [see [23] for an overview] and many of those are
best suited as immunological read out target structures.
To the best of our knowledge, such a high number of
specific antigens have not been identified for any other
tumor entity.
Several studies have shown that fusion cells have the
potential to induce CD4
+ as well as CD8
+ T-cell
mediated antitumor immunity, protection from an other-
wise lethal challenge of tumor, and even regression of
established metastatic disease [15,26-28]. In vitro stimula-
tion of CD3
+ T cells with the two fusion clones that were
analyzed in detail here induced effector T cells with
strong cytotoxic potential that is HLA-A02-restricted
and mediated mainly by CD8
+ T cells. Moreover, these
polyclonal T cell responses are directed against MSI
+
tumor cells. ELISpot assays revealed that at least a part of
this reactivity was due to specific recognition of FSPs. In
addition to the four FSPs specifically recognized in the
ELISpot analysis shown in Figure 5, we observed signifi-
cant reactions against two additional FSPs (OGT(-1) and
AC-1(-1)) in repetition analysis (data not shown). Lack of
reactivity towards microsatellite stable tumor cells but
target cell recognition of yet another tumor entity dis-
playing the MSI phenotype strongly argue for MSI
+
tumor antigens shared between those tumor entities.
Thus, this is the first report on the induction of a specific
immune response towards MSI-induced FSPs without
the use of artificial peptides.
Another interesting aspect was the comparably stron-
ger reactivity of fusion cell stimulated T cells to the
fusion clone than to the HCT116 fusion partner. This
could mainly be attributed to the CD8
+ T cells. As
explanation, we consider a better presentation to the T
cells of FSPs by the fusion clones than by the HCT116
tumor cells or a better activation of low avidity T cells
as likely.
In conclusion, our findings further support the idea
that APC/tumor cell fusions represent an attractive
approach to cancer immunotherapy [29,30]. We suggest
that semiallogenic cell hybrids of human MSI
+ tumor
cells and CD40 Bs are a feasible approach to generate
polyepitope vaccines with the capacity to induce polyva-
lent immune responses. Future studies with primary
tumor cells of MSI
+ patients fused to autologous APCs
should further address the feasibility of this approach in
a complete autologous situation as this may have impor-
tant clinical implications for the treatment of MSI
+
tumors. However, the in vivo efficacy of such cell-based
MSI
+ cancer vaccines must be proven either in appro-
priate animal models or in carefully designed small clini-
cal studies including cases of very advanced disease.
Conclusions
In the presented study we demonstrate the potential of
semiallogeneic cellular fusions of MSI
+ colorectal carci-
noma cells and activated B cells to induce FSP-specific
T cells. Selection of fusion cell clones facilitates detailed
analysis of the antigen-presenting capacity as well as the
repertoire of expressed frameshift antigens. These fusion
clones were able to stimulate T cells which showed spe-
cificity for the fusion cells themselves and additionally
for the MSI
+ carcinoma cell fusion partner. Moreover,
we were able to demonstrate that at least part of this
antitumoral potential was due to the specific induction
of T cells recognizing several FSPs. Thus, these data
underline the high potential of cellular fusions to induce
tumor-specific T cells and may contribute to the devel-
opment of novel cellular immunotherapies.
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